Papulopustular rosacea during nivolumab therapy of metastatic squamous cell esophageal carcinoma.
Dermatol Online J
; 27(9)2021 Sep 15.
Article
en En
| MEDLINE
| ID: mdl-34755982
ABSTRACT
We present a 76-year old man who developed papulopustular rosacea after receiving nivolumab treatment for his esophageal carcinoma, metastatic to the lungs. Nivolumab is an emerging cancer therapy whose immune-related adverse events are still not fully recognized and likely underreported. The treatment has been reported to cause a myriad of cutaneous immune-related adverse events. However, nivolumab-induced-papulopustular rosacea has been scarcely reported. Thus, this case presents a clinically important finding that physicians should be aware of when seeing patients on nivolumab therapy.
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Neoplasias Esofágicas
/
Carcinoma de Células Escamosas
/
Rosácea
/
Antineoplásicos Inmunológicos
/
Nivolumab
Límite:
Aged
/
Humans
/
Male
Idioma:
En
Revista:
Dermatol Online J
Asunto de la revista:
DERMATOLOGIA
Año:
2021
Tipo del documento:
Article